• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Formulae for calculating subgroup disease burden from overall and reported or assumed relative burden estimates.根据总体以及报告的或假设的相对负担估计值计算亚组疾病负担的公式。
Dialogues Health. 2025 Apr 18;6:100216. doi: 10.1016/j.dialog.2025.100216. eCollection 2025 Jun.
2
Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.在流行地区,服用抗叶酸抗疟药物的人群中,叶酸补充剂与疟疾易感性和严重程度的关系。
Cochrane Database Syst Rev. 2022 Feb 1;2(2022):CD014217. doi: 10.1002/14651858.CD014217.
3
Global incidence, prevalence, years lived with disability (YLDs), disability-adjusted life-years (DALYs), and healthy life expectancy (HALE) for 371 diseases and injuries in 204 countries and territories and 811 subnational locations, 1990-2021: a systematic analysis for the Global Burden of Disease Study 2021.全球疾病、伤害和危险因素负担研究 2021 年,1990-2021 年全球 204 个国家和地区及 811 个次国家地区 371 种疾病和伤害的发病率、患病率、伤残损失生命年(YLDs)、伤残调整生命年(DALYs)以及健康期望寿命(HALE):系统分析
Lancet. 2024 May 18;403(10440):2133-2161. doi: 10.1016/S0140-6736(24)00757-8. Epub 2024 Apr 17.
4
Global burden and strength of evidence for 88 risk factors in 204 countries and 811 subnational locations, 1990-2021: a systematic analysis for the Global Burden of Disease Study 2021.全球疾病负担研究 2021 年在 204 个国家和地区、811 个次国家级地点对 88 种风险因素的全球负担和证据强度:系统分析。
Lancet. 2024 May 18;403(10440):2162-2203. doi: 10.1016/S0140-6736(24)00933-4.
5
Deployment of personnel to military operations: impact on mental health and social functioning.人员部署到军事行动中:对心理健康和社会功能的影响。
Campbell Syst Rev. 2018 Jun 1;14(1):1-127. doi: 10.4073/csr.2018.6. eCollection 2018.
6
Impact of summer programmes on the outcomes of disadvantaged or 'at risk' young people: A systematic review.暑期项目对处境不利或“有风险”的年轻人的影响:一项系统综述。
Campbell Syst Rev. 2024 Jun 13;20(2):e1406. doi: 10.1002/cl2.1406. eCollection 2024 Jun.
7
The effect of exposure to long working hours on stroke: A systematic review and meta-analysis from the WHO/ILO Joint Estimates of the Work-related Burden of Disease and Injury.长时间工作暴露对中风的影响:来自世卫组织/国际劳工组织工作相关疾病和伤害负担联合估算的系统评价和荟萃分析。
Environ Int. 2020 Sep;142:105746. doi: 10.1016/j.envint.2020.105746. Epub 2020 Jun 3.
8
Global, regional, and national estimates of the population at increased risk of severe COVID-19 due to underlying health conditions in 2020: a modelling study.2020 年,由于潜在健康状况,全球、区域和国家估计有多少人面临 COVID-19 重症风险增加:一项建模研究。
Lancet Glob Health. 2020 Aug;8(8):e1003-e1017. doi: 10.1016/S2214-109X(20)30264-3. Epub 2020 Jun 15.
9
Small class sizes for improving student achievement in primary and secondary schools: a systematic review.小班教学对提高中小学学生成绩的影响:一项系统综述。
Campbell Syst Rev. 2018 Oct 11;14(1):1-107. doi: 10.4073/csr.2018.10. eCollection 2018.
10
Effects of short-term exposure to air pollution on hospital admissions of young children for acute lower respiratory infections in Ho Chi Minh City, Vietnam.越南胡志明市短期暴露于空气污染对幼儿急性下呼吸道感染住院率的影响。
Res Rep Health Eff Inst. 2012 Jun(169):5-72; discussion 73-83.

本文引用的文献

1
Health and economic impact of the 21-valent pneumococcal conjugate vaccine (V116) for adults in Japan: a delta price approach.21价肺炎球菌结合疫苗(V116)对日本成年人的健康和经济影响:一种增量价格法
J Med Econ. 2025 Dec;28(1):136-145. doi: 10.1080/13696998.2024.2445429. Epub 2025 Jan 2.
2
Cost-Effectiveness Analysis of the Use of V116, a 21-Valent Pneumococcal Conjugate Vaccine, in Vaccine-Naïve Adults Aged ≥ 65 Years in the United States.21价肺炎球菌结合疫苗V116在美国65岁及以上未接种过疫苗的成年人中使用的成本效益分析。
Infect Dis Ther. 2024 Dec;13(12):2597-2615. doi: 10.1007/s40121-024-01067-1. Epub 2024 Nov 8.
3
Lifetime Health and Economic Burden of Invasive Pneumococcal Diseases Attributable to V116 Serotypes Among Adults in the United States.美国成年人中V116血清型侵袭性肺炎球菌疾病的终生健康和经济负担
Infect Dis Ther. 2024 Jul;13(7):1501-1514. doi: 10.1007/s40121-024-00988-1. Epub 2024 May 25.
4
Cost-effectiveness of an in-development adult-formulated 21-valent pneumococcal conjugate vaccine in US adults aged 50 years or older.一种正在研发的成人型 21 价肺炎球菌结合疫苗在 50 岁及以上美国成年人中的成本效益。
Vaccine. 2024 Apr 30;42(12):3024-3032. doi: 10.1016/j.vaccine.2024.04.002. Epub 2024 Apr 4.
5
Pneumococcal Vaccination Strategies in 50-Year-Olds to Decrease Racial Disparities: A US Societal Perspective Cost-Effectiveness Analysis.50 岁人群中肺炎球菌疫苗接种策略以减少种族差异:美国社会视角下的成本效益分析。
Value Health. 2024 Jun;27(6):721-729. doi: 10.1016/j.jval.2024.02.021. Epub 2024 Mar 8.
6
Societal Cost of Racial Pneumococcal Disease Disparities in US Adults Aged 50 Years or Older.美国50岁及以上成年人种族肺炎球菌疾病差异的社会成本
Appl Health Econ Health Policy. 2024 Jan;22(1):61-71. doi: 10.1007/s40258-023-00854-0. Epub 2023 Nov 15.
7
Understanding the age spectrum of respiratory syncytial virus associated hospitalisation and mortality burden based on statistical modelling methods: a systematic analysis.基于统计建模方法理解呼吸道合胞病毒相关住院和死亡负担的年龄谱:系统分析。
BMC Med. 2023 Jun 26;21(1):224. doi: 10.1186/s12916-023-02932-5.
8
Cost-effectiveness of an in-development adult-formulated pneumococcal vaccine in older US adults.开发中的成人剂型肺炎球菌疫苗在老年美国成年人中的成本效益。
Vaccine. 2023 Jul 5;41(30):4431-4437. doi: 10.1016/j.vaccine.2023.06.007. Epub 2023 Jun 12.
9
Cost-effectiveness of revised US pneumococcal vaccination recommendations in underserved minority adults < 65-years-old.修订后的美国肺炎球菌疫苗接种建议在服务不足的少数族裔成年人 < 65 岁人群中的成本效益
Vaccine. 2022 Nov 28;40(50):7312-7320. doi: 10.1016/j.vaccine.2022.10.066. Epub 2022 Nov 3.
10
Expanded Analysis of 20 Pneumococcal Serotypes Associated With Radiographically Confirmed Community-acquired Pneumonia in Hospitalized US Adults.20 种与美国住院成人影像学确诊社区获得性肺炎相关的肺炎球菌血清型的扩展分析。
Clin Infect Dis. 2021 Oct 5;73(7):1216-1222. doi: 10.1093/cid/ciab375.

根据总体以及报告的或假设的相对负担估计值计算亚组疾病负担的公式。

Formulae for calculating subgroup disease burden from overall and reported or assumed relative burden estimates.

作者信息

Owusu-Edusei Kwame, Deb Arijita, Elbasha Elamin H

机构信息

Merck & Co., Inc., Rahway, NJ, USA.

GSK, Upper Province, PA, USA.

出版信息

Dialogues Health. 2025 Apr 18;6:100216. doi: 10.1016/j.dialog.2025.100216. eCollection 2025 Jun.

DOI:10.1016/j.dialog.2025.100216
PMID:40342545
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12059317/
Abstract

BACKGROUND

The risk of disease varies across populations based on factors like age, sex, race, ethnicity, socioeconomic status, and underlying medical conditions. Subgroup or subpopulation data are critical in planning, executing and evaluating public health interventions. However, most studies report the values for the overall (total) population with little or no information on the subgroups. As a result, finding subgroup specific data can be challenging.

OBJECTIVE

In this report, a set of formulae that can be used to calculate subgroup or subpopulation data using the overall estimates and the reported or assumed relative estimates were derived.

METHODS

A simple numerical example was used to illustrate the methodology. Next, symbolic formula for calculating the burden (e.g., incidence, prevalence, or average cost) for 3 (and extended to number of) subgroups or subpopulations were derived. To account for uncertainty in the data, two statistical methods were used to estimate confidence intervals for the point estimates.

RESULTS

The derived formulae indicated that each subgroup or subpopulation's burden (incidence, prevalence, or average cost) can be calculated as the overall burden adjusted by the ratio of that subgroup or subpopulation's relative burden to the sum of the proportion-weighted relative burden (incidence, prevalence, or average cost) of all the subgroups or subpopulations within the population.

CONCLUSION

These formulae can help to avoid or minimize potential quantitative and qualitative errors in subgroup or subpopulation disease burden estimates used for health research, interventions and/or policy analyses or deliberations.

摘要

背景

基于年龄、性别、种族、民族、社会经济地位和潜在医疗状况等因素,不同人群的疾病风险存在差异。亚组或亚人群数据对于规划、实施和评估公共卫生干预措施至关重要。然而,大多数研究报告的是总体(全部)人群的数据,而关于亚组的信息很少或没有。因此,查找亚组特定数据可能具有挑战性。

目的

在本报告中,推导了一组可用于使用总体估计值以及报告的或假设的相对估计值来计算亚组或亚人群数据的公式。

方法

使用一个简单的数值示例来说明该方法。接下来,推导了用于计算3个(并扩展到任意数量)亚组或亚人群负担(如发病率、患病率或平均成本)的符号公式。为了考虑数据中的不确定性,使用两种统计方法来估计点估计值的置信区间。

结果

推导的公式表明,每个亚组或亚人群的负担(发病率、患病率或平均成本)可以通过将总体负担乘以该亚组或亚人群的相对负担与人群中所有亚组或亚人群的比例加权相对负担(发病率、患病率或平均成本)之和的比率来计算。

结论

这些公式有助于避免或最小化用于健康研究、干预措施和/或政策分析或审议的亚组或亚人群疾病负担估计中的潜在定量和定性误差。